Načítá se...

Canagliflozin-current status in the treatment of type 2 diabetes mellitus with focus on clinical trial data

Canagliflozin (CFZ) is a member of new class of glucose lowering agents, sodium-glucose co-transporter (SGLT) inhibitors, which got approval by food and drug administration. It has insulin independent action by blocking the transporter protein SGLT2 in the kidneys, resulting in urinary glucose excre...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Bhatia, Jagriti, Gamad, Nanda, Bharti, Saurabh, Arya, Dharamvir Singh
Médium: Artigo
Jazyk:Inglês
Vydáno: Baishideng Publishing Group Inc 2014
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4058745/
https://ncbi.nlm.nih.gov/pubmed/24936262
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4239/wjd.v5.i3.399
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!